This website uses cookies to help us improve the website and give you the best experience.
By using the website you agree to our use of cookies. Read more

You appear to be from the USA. Would like to proceed to Products available in the USA?

Use of the UniQ® ICTP RIA kit in monitoring bone metastasis of cancer

Bone metastasis of cancer

Osteolytic bone metastases are frequent in patients with advanced cancer of the breast, lung, and (to a lesser extent) the prostate. Roentgenography, bone scintigraphy, and bone biopsies are commonly used for the early identification and follow-up of these conditions. These methods have though marked shortcomings as they are all static methods giving a picture of the current situation in bone but not telling about rate of changes taking place in bone. Metabolic bone markers have been shown to be a useful tool for monitoring metastatic bone activity.

It has been shown that there are two different pathways of bone resorption: the cathepsin K-mediated pathway, which is active during physiological resorption of bone, and the matrix metalloproteinase pathway, which functions mainly in pathological situations. ICTP specifically reflects matrix metalloproteinase-mediated pathological degradation of bone collagen (1, 2). ICTP is thus a highly specific marker of bone degradation in bone metastasis and constitutes a sensitive and easy means of detecting bone metastases of cancer (3-5) and monitoring the response to treatment (6).


1. Garnero P et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-867.  2. Sassi ML et al. Immunochemical characterisation of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 2000;26:367-373. 3. Leeming D et al. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:32-38. 4. Santala M et al. Comparison of carboxyterminal telopeptide of type I collagen (ICTP) and CA 125 as predictors of prognosis in ovarian cancer. Anticanc Res 2004;24:1057-1062. 5. Voorzanger-Rousselot N et al. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer 2006;95:506-514. 6. Lein M et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur Urol 2007;52:1381-7.


Read more: UniQ ICTP

Published January 4, 2017